- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Pilot Suggests Additional Benefits of Entresto in Patients With HFrEF
When the sympathetic nervous system is unregulated, it can lead to high blood pressure and elevated heart rate.
The combination of sacubitril-valsartan, sold as Entresto, that is currently the only FDA-approved for patients across the spectrum of heart failure, may have additional benefits for those with heart failure with reduced ejection fraction (HFrEF), findings of a pilot study show.
Results reported recently in Autonomic Neuroscience examined the effect of the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) on chronic sympathetic nervous system (SNS) overactivity. Sacubitril-valsartan has been shown to cut the risk of death from cardiovascular causes as well as hospitalization from heart failure for those with HFrEF.
When the SNS is unregulated, it can lead to high blood pressure and elevated heart rate. The single-arm, open-label prospective study sought to examine the physiological benefits of sacubitril-valsartan; the pilot looked at how the drug inhibited SNS effects in patients with HFrEF, thus offering additional benefits beyond those already demonstrated in clinical trials.
The pilot study was very small, with just 9 patients who were all stable in either New York Heart Association Class II or Class III. Patients with HFrEF were assessed; their muscle sympathetic nerve activity (MSNA) heart rate, and arterial blood pressure were assessed; their average age was 69 years, with a body mass index (BMI) of 28.6 kg/m2. All were on guideline directed treatment and were later started on sacubitril-valsartan. After 2 months, all measurements were repeated, with the following results:
- Sacubitril-valsartan reduced MSNA burst frequency; patients went from 43 ± 10 bursts/min to 36 ± 10 bursts/min; P = .05.
- Burst incidence also declined, from 68 ± 16 bursts/100 heartbeats to 55 ± 16 bursts/100 heartbeats; P =.02.
- Heart rate and blood pressure were unchanged following treatment; P > .05.
According to the authors, “The preliminary findings provide new evidence regarding the ability of sacubitril-valsartan to rapidly reduce SNS activity in patients with HFrEF, suggesting the presence of a novel sympathoinhibitory effect of this new drug class.”
Reference
Bunsawat K, Ratchford SM, Alpenglow JK, et al. Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: a pilot study. Auton Neurosci. Published online June 24, 2021. doi: 10.1016/j.autneu.2021.102834
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Intermountain Healthcare and Story Health Partner to Optimize Rural Heart Failure Care
February 7th 2023On this episode of Managed Care Cast, we speak with Tom Stanis, CEO and cofounder of Story Health, and Phillip Wood, Intermountain Ventures program director, on how their partnership came about, how it is going so far, and the future of their collaboration.
Listen
Midodrine Use Linked to Decrease in HFrEF-Related ED Visits
March 23rd 2024However, researchers saw higher risks of respiratory failure, longer stays in the intensive care unit, increased hospitalizations, and elevated mortality rates in patients with heart failure with reduced ejection fraction (HFrEF) taking the antihypotensive medication.
Read More
